Inventiva: Biotechnological Inventiva indicators main deal in China associated to soda ailments

(BFM Bourse) – The Burgundy firm has signed an agreement with China’s Sino Biopharma to develop and market its lanifibranor molecule in China. Inventiva will receive up to 290 million euros to finance the final phase of studies for its treatment against “soda disease.” The latter is characterized by an influx of fat into the liver, which can cause lesions up to cirrhosis and cancer.

Inventiva, a French biotech company listed in France and the United States, has signed an agreement with China’s Sino Biopharma that will see it receive up to $290 million (€293.6 million) to develop its treatment against “soda disease.” cirrhosis due to fat and sugar.

This agreement, which caused Inventiva’s share price to jump 25% on the Paris Stock Exchange, foresees the payment of clinical milestones, the first of which is 12 million euros, to continue the development of the treatment, which is currently being evaluated in a phase III clinical study (the last phase of clinical tests before possible marketing), Inventiva said in a press release published on the night from Wednesday to Thursday.

Sino Biopharm, a major Chinese pharmaceutical group, will oversee the development and commercialization in China of lanifibranor, a molecule that the US Food and Drug Administration (FDA) has granted “breakthrough therapy” (“particularly innovative treatment”) status for after the publication of positive results from the first clinical studies .

This treatment, which has already received a very significant funding of 50 million euros from the European Investment Bank, targets a market estimated at between 20 and 30 billion dollars, according to independent experts.

200,000 people affected by “soda disease” in France

Lanifibranor is a treatment for “non-alcoholic steatohepatitis” (Nash), a deadly disease known as “fatty liver” or “soda”, which probably affects 10% of Americans. In China, the disease could affect between 3 and 6% of the population.

At this level of diseased people, liver transplantation, the only cure to avoid death, becomes impossible, given the few liver donations available. In France, according to Insermo, this “junk food” disease of the 21st century would affect more than 200,000 people in a severe stage.

Payments under the contract with Sino Biopharma will fund the third and final phase of pre-marketing studies of the Nash treatment. This phase, which concerns human trials, should be completed by the end of 2025.

The 100-employee biotech company, headquartered in Daix, near Dijon, is one of the few French companies listed on both the Paris Stock Exchange and Nasdaq in New York. It also has a subsidiary in the United States.

(with AFP)

SS – ©2022 BFM stock exchange

Are you following this action?

Receive all information about INVENTIVA in real time:

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button